Latest Articles
With the rapid increase in prostate cancer, it has become the most common cancer among Korean men. T.. - 매일경제
With the rapid increase in prostate cancer, it has become the most common cancer among Korean men. T.. 매일경제
Published: Jan. 20, 2026, 8:35 p.m.
Ulsan team reports single-port robotic surgery removing colorectal and endometrial cancers - koreabiomed.com
Ulsan team reports single-port robotic surgery removing colorectal and endometrial cancers koreabiomed.com
Published: Jan. 15, 2026, 6:21 a.m.
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ - Chosunbiz
Onconic Therapeutics wins IND approval for phase 1b–2 gastric cancer trial in Korea - CHOSUNBIZ Chosunbiz
Published: Dec. 17, 2025, 1:04 a.m.
Endometrial cancer treatment enters a paradigm shift: expert - koreabiomed.com
Endometrial cancer treatment enters a paradigm shift: expert koreabiomed.com
Published: Dec. 16, 2025, 8:01 a.m.
[Medical Bulletin] Top Robotic Surgeon Kyung-Ah Jeong to Lead Korean Gynecologic Society - 동아사이언스
[Medical Bulletin] Top Robotic Surgeon Kyung-Ah Jeong to Lead Korean Gynecologic Society 동아사이언스
Published: Dec. 8, 2025, 8:44 a.m.
Professor Chung Kyung-ah, the new chairman of the Korean Society of Ob - SportsChosun
Professor Chung Kyung-ah, the new chairman of the Korean Society of Ob SportsChosun
Published: Dec. 8, 2025, 2:33 a.m.
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy - koreabiomed.com
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy koreabiomed.com
Published: Dec. 1, 2025, 6:49 a.m.
Renowned Korean Japanese surgeon accused of defacing sacred sites in Japan - Moneycontrol
Renowned Korean Japanese surgeon accused of defacing sacred sites in Japan Moneycontrol
Published: Nov. 12, 2025, 9:54 a.m.
Treatment paradigm for recurrent endometriosis shifts from surgery to medication - koreabiomed.com
Treatment paradigm for recurrent endometriosis shifts from surgery to medication koreabiomed.com
Published: Oct. 24, 2025, 8:01 a.m.
Insurance coverage for GSK's Jemperli expanded to 1st-line endometrial cancer in Korea - koreabiomed.com
Insurance coverage for GSK's Jemperli expanded to 1st-line endometrial cancer in Korea koreabiomed.com
Published: Sept. 29, 2025, 8:16 a.m.
Link copied to clipboard!